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Abstract  Phyllodes  tumour  corresponds  to  1%  of  breast  primary  tumours.  Its  primary  treat-
ment is  presently  surgical  and,  for  several  reasons,  it  usually  requires  breast  reconstruction.
First of  all,  an  important  breast  volume  is  often  removed,  not  only  because  it  can  easily  achieve
great dimensions,  thanks  to  it  fast  growing  potential,  but  also  because  wide  excision  is  recom-
mended to  avoid  its  frequent  but  unpredictable  local  recurrence  (meaning  that  ideal  tumour
resection  margins  are  unknown).  Second,  it  frequently  affects  young  woman  with  more  aesthetic
concerns.
We present  a  case  of  phyllodes  tumour  recurrence  where  oncoplastic  surgery  was  necessary
at both  episodes  and  discuss  the  literature  controversies  on  this  subject,  mainly  related  to
treatment and  prognosis  prediction  factors.
© 2017  SESPM.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights  reserved.
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Pronóstico
Tumor  phyllodes  gigante  --  Caso  clínico,  cirurgía  oncoplástica  y  controversias  en  la
literatura
Resumen  El  tumor  phyllodes  representa  el  1%  de  los  tumores  primarios  de  mama.  Actual-
mente, su  tratamiento  primario  es  la  cirugía  y,  por  muchas  razones,  requiere  normalmente
reconstrucción  de  mama.  Primeramente,  porque  a  menudo  es  extirpado  un  importante  volu-
men de  mama,  no  sólo  porque  el  tumor  puede  adquirir  grandes  dimensiones  gracias  a  su  alto
potencial de  crecimiento,  sino  también  porque  es  recomendado  una  amplia  excisión  para  evitar
su frecuente  pero  impredecible  recidiva  local  (los  márgenes  quirúrgicos  ideales  no  son  cono-
cidos). Segundo,  porque  afecta  frecuentemente  a  mujeres  jóvenes  con  más  preocupaciones
estéticas.
ecid
y  discutimos  las  controversias  en  la  literatura  sobre  este  tema,
tratamiento  y  a  los  factores  pronósticos.
or  Elsevier  Espan˜a,  S.L.U.  Todos  los  derechos  reservados.Presentamos  un  caso  de  r
saria en  ambos  episodios  
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Considering  the  tumour  dimension,  a radical  surgery,0  
ntroduction
hyllodes  tumour  (PT)  is  a  fibroepithelial  tumour  which
ccounts  for  1%  of  breast  primary  tumours.1 The  term
hyllodes  (which  means  ‘‘leaflike’’)  refers  to  its  histologic
ppearance  in  which  a  double  layer  epithelial  component  is
urrounded  by  its  hypercellular  stromal/mesenchymal  com-
onent.  The  WHO  has  defined  several  histologic  features
hat  help  differentiate  PT  from  fibroadenomas  and  clas-
ify  them  into  benign,  borderline  or  malignant  (degree  of
tromal  cellularity,  atypia  and  overgrowth,  mitotic  count,
umour  borders  behaviour  and  the  presence  of  malignant
eterologous  components).1 However,  PTs  intratumoural
eterogeneity,  and  the  continuous  spectrum  between  benign
nd  malignant  categories,  makes  their  grading  accuracy
nd  reproducibility  less  achievable.2 Molecular  markers  like
ED12  (Mediator  of  RNA  polymerase  II  transcription)  muta-
ions  or  DNA  ploidy  have  been  studied  to  help  define  more
recisely  the  tumour  clinical  behaviour.  MED12  mutations
s  frequently  associated  with  a  longer  disease-free  survival
hile  its  absence  is  associated  with  a  higher  recurrence
ate.3 Aneuploidy  (versus  diploidy)  is  also  associated  with  an
ncreased  recurrence  rate.4 PTs  usually  have  clearly  defined
argins  and  can  be  surgically  ‘‘enucleated’’,  however  they
re  well  known  for  their  recurrence  potential  --  consensus
s  lacking  to  define  which  optimal  margins  protect  against
ecurrence.2
Mainly  the  malignant  PT  can  metastasize  hematogenously
like  sarcomas).  Metastasis  are  usually  of  the  stromal  compo-
ent,  with  loss  of  the  epithelial-stromal  interdependence.2
Because  PT  arise  in  women  between  the  age  of  40  and  50
ears  and  because  of  their  usual  rapidly  growing  capability
therefore  presenting  with  large  volumes,  5--10  cm),  they
epresent  an  oncoplastic  challenge.5 We  report  a  recurring
igure  1  Initial  presentation  clinical  and  imagiologic  (MRI)  featu
ith a  precocious  contrast  enhancement  --  type  2  curve).
r
a
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T  and  the  offered  breast  reconstruction  treatments  in  each
ituation.
ase report
 58  years  old  woman,  heavy  smoker,  otherwise  healthy,
ith  no  relevant  personal  or  familiar  history,  presented  with
 painful,  rapidly  growing,  breast  mass  with  inflammatory
haracteristics  (but  without  linfedema).  To  palpation  it  was
 multinodular  mass  with  firm  consistency  and  no  palpable
ymph  nodes.  For  years  she  had  noticed  a  stable  small  lump
n  the  same  location,  however,  after  reassured  by  her  doc-
or,  she  had  never  had,  so  far,  a  breast  imagiologic  exam
Fig.  1).
A  core  needle  biopsy  revealed  a fibroepithelial  tumour
ith  hypercellular  stroma,  no  mitosis,  no  pleomorphism  or
eterologous  components.  These  findings  were  suggestive  of
 benign  PT  but  total  excision  was  required  for  a  conclusive
iagnostic.
The  magnetic  resonance  imaging  (MRI)  showed  a
3  ×  11  cm  ovoid  shaped  polylobulated  mass  in  the  left
reast,  that  had  an  heterogeneous  appearance  with  50%  of
he  mass  occupied  by  cystic  areas  and  the  rest  by  solid
reas  with  a  rapid  contrast  enhancement  pattern  (type
 curve).  The  pectoralis  major  muscle  did  not  appear  to
ontact  with  the  breast  tumour.  The  regional  lymph  nodes
nd  the  right  breast  where  uncharacteristic.  The  left  breast
as  classified  as  BIRADS  4b  (Breast  Imaging-Reporting  and
ata  System  Classification)  and  the  right  breast  as  BiRads  2
Fig.  1).res  (left  breast  with  both  cystic  and  solid  areas,  the  last  ones
ather  than  a  conservative  approach,  was  considered  the
ppropriate  surgical  option  for  this  case.  A  simple  mastec-
omy  with  maximum  breast  tissue  extirpation  was  provided,
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sponded to  the  pectoralis  major  muscle  fascia.  It  was  macrosco
wielding  wide  macroscopic  margins  (confirmed  by  intra-
operatory  pathological  evaluation).  Due  to  the  important
cutaneous  deficit,  immediate  reconstruction  with  a  flap  was
necessary.  Among  the  flap  possibilities,  latissimus  dorsi  mus-
cle  was  the  best  suitable  flap  due  to  smoking  habits.  A
symmetrization  mammoplasty  was  done  in  the  right  breast
(Fig.  2).  The  histologic  result  was  a  15  ×  11  ×  10  cm  border-
line  PT  with  the  histologic  features  detailed  in  Table  1.  The
right  breast  fragments  had  normal  histology.
The  patient  follow-up  was  done  clinically  and  with  an
annual  mammogram.  Four  years  and  7  months  after  the
first  surgery,  a  rapidly  growing  mass  was  clinically  evident
near  the  medial  end  of  the  surgical  incision  and  the  histo-
logic  confirmation  of  the  recurrence  revealed  a  borderline
PT  (with  8  mitosis  per  10  high  power  fields).  MRI  showed
a  8  ×  7  ×  5  cm  tumour  and  the  rapid  contrast  enhancement
t
t
o
Table  1  Histopathology  of  primary  and  recurrent  tumour.
Primary  tumour  
Size  15  ×  11  ×  10  cm  
Histologic  architecture  Leaf-like  (mixed
phylloid/periducta
architecture)
Presence of  necrosis  Yes  
Epithelial  component  Present  
Stromal cellularity  Moderate  
Stromal  atypia  Moderate  
Stromal  overgrowth  Absent  
Stromal  mitotic  activity  Few  (3  mitosis  per
power  fields)
Tumour borders  behaviour  Focally  permeativ
Malignant heterologous  components  Absent  
Linfovascular  invasion  Absent  
Conclusion  Borderline  phylloiuscle  flap  (and  breast  expander).  The  posterior  margin  corre-
lly  --  and  microscopically  confirmed  --  free  of  tumour.
ith  wash-out  (type  3  curve),  lymph  nodes  were  unremark-
ble  (Fig.  3).
Excision  of  the  tumour,  together  with  the  breast  implant,
art  of  the  pectoralis  major  muscle  (6  ×  3  ×  2.5  cm)  and  par-
ial  resection  of  the  breast  implant  capsule  was  feasible  in
ne  single  block.  A  local  tissue  flap  advancement  (skin  and
emaining  latissimus  dorsi  muscle)  was  enough  to  ensure
losure  with  an  expander  placed.  This  option  conciliated  a
umour  excision  with  safety  margins,  and  a  definitive  recon-
truction,  avoiding  the  sacrifice  of  another  flap  (Fig.  4).
The  histologic  analysis  revealed  total  absence  of  epi-
helial  cells  with  an  isolated  mesenchymal  component
ecurrence.  This  stromal  overgrowth  was  the  only  fea-
ure  suggestive  of  malignant  phylloid  tumour  according  to
he  WHO’s  international  histologic  classification.  All  the
ther  histologic  characteristic  were  typical  of  borderline
Recurrent  tumour
7.5  ×  6  ×  3.5  cm
l  stroma
Fusocellular/fasciculated
(isolated  recurrence  of
mesenchymatous  component)
Yes
Absent  (only
fibroblastic/myofibroblastic
cells)
Moderate
Moderate
Present
 10  high Few  (1--2  mitosis  per  10  high
power  fields)
e  Focally  permeative
Absent
Absent
d  tumour  Isolated  mesenchymatous
recurrence  of  borderline
phylloid  tumour
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bFigure  3  Clinical  and  ima
moderate  stromal  cellularity  and  atypia)  or  benign  (less
han  5  mitosis  per  10  high  power  fields)  phylloid  tumour.  If
alignant  heterologous  components  were  present  it  would
e  enough  to  qualify  a  malignant  phylloid  tumour.  In  this
ase  an  isolated  mesenchymatous  recurrence  of  a  borderline
hylloid  tumour  was  diagnosed.
DNA  ploidy  analysis  with  flow  cytometry  showed  diploidy
this  was  not  analyzed  in  the  primary  tumour).
D
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igure  4  The  wide  excision  of  the  local  recurrence  was  accomplis
astissimus dorsi  muscle  (together  with  the  breast  implant  and  a  segm
y a  local  tissue  advancement  flap  --  initially  corresponding  to  the  tigic  features  of  recurrence.
The  patient  has  presently  a  2  months  follow-up  period
nd  continues  in  the  expansion  process.iscussion
 clinically  benign  lump,  even  if  stable  for  years
efore,  should  always  call  the  attention  if  it  becomes
hed  with  the  partial  resection  of  the  pectoralis  major  and  the
ent  of  its  capsule),  in  one  unique  piece.  Closure  was  achieved
ssue  covering  the  lower  and  lateral  part  of  the  breast  implant.
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hypersensitive  or  tender  after  menopause,  grows  quickly  or
becomes  painful  no  matter  what  age.  Once  detected,  an
initial  ultrasound  or  ultrasound  plus  mammography  (accord-
ing  to  the  patient  age  or  breast  density)  to  assess  its  initial
imagiologic  characteristics  should  be  done.  In  doubt,  a  core
biopsy  is  usually  conclusive.  Assisted  vacuum  biopsy  or  surgi-
cal  excision  is  both  valid  options  if  the  lesion  is  symptomatic
or  if  a  complete  histologic  evaluation  is  required.
So  far  there  is  no  precise  consensus  determining  which
suspected  or  histologic  confirmed  fibroepithelial  lesions
should  be  totally  removed.  However,  even  if  imagiologi-
cally  benign,  a  biopsy  must  always  be  done  before  surgery
(this  will  also  help  planning  enucleation  for  fibroadeno-
mas  versus  wide  excision  for  PTs).  Complete  excision  of  all
fibroepithelial  lesions  probably  is  an  overtreatment  and  is
not  recommended.
In  case  of  PT,  although  the  primary  treatment  is  surgi-
cal,  optimal  margins  are  not  defined.  The  French  College  of
Gynecologists  and  Obstetricians  has  recently  recommended,
with  low  quality  of  evidence  (grade  C  recommendation),
clear  margins  for  grade  1  PT  (benign)  and  10  mm  margins  for
grade  2  PT  (borderline).6 For  local  recurrence  or  malignant
PT,  total  mastectomy  is  the  preferred  approach.5
It  is  important  to  inform  the  patient  with  PT  about  the
recurrence  and  metastatic  risk  according  to  the  histologic
features  of  the  tumour  (even  if,  in  some  cases,  the  histolog-
ical  grade  alone  does  not  correctly  predicts  the  biological
aggressiveness  of  the  tumour  and  the  clinical  prognosis).7,8
After  many  classifications  have  been  proposed,  the  2003
WHO  Phylloid  tumour  classification  has  been  the  most  widely
accepted  and  commonly  used.  Considering  the  poor  rela-
tion  between  histologic  grade  and  prognosis,  several  authors
have  tried  to  identify  genetic  or  molecular  markers  (MED12
mutations,3 DNA  ploidy,4 collagen  type  III  1,9 others).10,11
This  has  been  a  hard  task  due  to  long  time  latency,  low  num-
ber  of  cases,  and  intratumoural  heterogeneity.11 Nowadays
this  markers  are  only  investigational,  and,  due  to  little  prog-
nostic  value,  none  has  been  recommended  for  routine  use.
Other  possible  prognostic  factors  have  been  published  like
older  age,  bigger  size,  presence  of  necrosis,  affected  mar-
gins  and  adjuvant  treatments.7,12 Precocious  recurrence  or
grade  progression  with  recurrence  are  also  of  undetermined
informative  value.  Research  continues  with  the  pursuit  of
identifying  more  objective  and  useful  variables,  needed  to
identify  high  risk  patients  who  would  benefit  from  wider
margins  or  adjuvant  therapies.
Breast  reconstruction  with  other  myocutaneous  flaps  like
deep/superficial  inferior  epigastric  perforator,  transverse
rectus  abdominus,  superior/inferior  gluteal  artery  flap  are
also  an  option.13 However,  they  require  a  higher  expertise
level  (involving  microsurgery),  a  longer  operative  time  and
hospital  stay.
Adjuvant  treatment  with  chemotherapy,8,14,15
radiotherapy8,14 or  hormonal  therapy  presently  have
no  clear  evidence  of  benefit  and  remain  controversial.
Given  the  rarity  of  PT,  randomized  controlled  trials  are
unexpected.  Nevertheless,  for  malignant  tumours,  adju-
vant  radiotherapy  registered  an  increase  but  its  use  was
established  based  on  an  individual  basis  (affected  margins,
increased  tumour  volumes,  recurrence,  others)16 as  it  has
not  shown  disease  free  or  overall  survival  benefit  (only  less
local  recurrence  rate).17
183
In  conclusion,  PT  represents  an  oncoplastic  challenge.
ts  natural  history  is  not  well  known  which  challenges  recur-
ence  prediction  or  its  risk  factors  identification.  Further
nowledge  about  this  tumour  may  have  surgical  and  other
herapeutic  implications.
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